


Spliceostatin A

Cat. No.:	HY-16466
CAS No.:	391611-36-2
Molecular Formula:	C ₂₈ H ₄₃ NO ₈
Molecular Weight:	521.64
Target:	SF3B1
Pathway:	Epigenetics
Storage:	-80°C, protect from light



BIOLOGICAL ACTIVITY

Description	Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells ^{[1][2][3]} .																
IC₅₀ & Target	IC50: 5.5 nM (wild-type SF3B1), 4.9 nM (SF3B1mutatant) ^[1]																
In Vitro	<p>Spliceostatin A (2.5-20 nM; 0-24 h) induces caspase-dependent apoptosis of CLL cells in a dose- and time-dependent manner^[1].</p> <p>Spliceostatin A (10 nM, 20 nM; 24 h) in combination with ABT-199 or ABT-263 synergises, augments apoptosis in CLL cells following IL4/CD40L (10 ng/mL, 300 ng/mL; 6 h) treatment, and reduce phosphorylation levels of related proteins^[1].</p> <p>Spliceostatin A inhibits the viability of normal B (CD19+) and T (CD3+) lymphocytes with IC₅₀s of 12.1 nM, and 61.7 nM, respectively^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>CLL cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 2.5 nM, 5 nM, 10 nM, and 20 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>0, 6 h, 12 h, and 24 h</td> </tr> <tr> <td>Result:</td> <td>Increased cell apoptosis.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>CLL cells</td> </tr> <tr> <td>Concentration:</td> <td>10 nM, and 20 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h; treated after 10 ng/mL IL4 and/or 300 ng/mL CD40L for 6 h</td> </tr> <tr> <td>Result:</td> <td>Decreased the level of PARP, phosphorylated STAT6 (pSTAT6), phosphorylated IκBα (pIκBα), Mcl-1L, Bcl-xL, Bcl-2 and Hsc70.</td> </tr> </table>	Cell Line:	CLL cells	Concentration:	0, 2.5 nM, 5 nM, 10 nM, and 20 nM	Incubation Time:	0, 6 h, 12 h, and 24 h	Result:	Increased cell apoptosis.	Cell Line:	CLL cells	Concentration:	10 nM, and 20 nM	Incubation Time:	24 h; treated after 10 ng/mL IL4 and/or 300 ng/mL CD40L for 6 h	Result:	Decreased the level of PARP, phosphorylated STAT6 (pSTAT6), phosphorylated IκBα (pIκBα), Mcl-1L, Bcl-xL, Bcl-2 and Hsc70.
Cell Line:	CLL cells																
Concentration:	0, 2.5 nM, 5 nM, 10 nM, and 20 nM																
Incubation Time:	0, 6 h, 12 h, and 24 h																
Result:	Increased cell apoptosis.																
Cell Line:	CLL cells																
Concentration:	10 nM, and 20 nM																
Incubation Time:	24 h; treated after 10 ng/mL IL4 and/or 300 ng/mL CD40L for 6 h																
Result:	Decreased the level of PARP, phosphorylated STAT6 (pSTAT6), phosphorylated IκBα (pIκBα), Mcl-1L, Bcl-xL, Bcl-2 and Hsc70.																

REFERENCES

- [1]. Larrayoz M, et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. *Leukemia*. 2016 Feb;30(2):351-60.
- [2]. Kaida D, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. *Nat Chem Biol*. 2007 Sep;3(9):576-83.
- [3]. Roybal GA, et al. Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. *Nucleic Acids Res*. 2010 Oct;38(19):6664-72.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA